povidone-iodine and Vaginitis

Underwater plasma discharge temporally produces several reactive radicals and/or free chlorine molecules in water, which is responsible for antimicrobial activity. Hence, it can simply sanitize tap water without disinfectant treatment. Additionally, the spraying technique using cleaning water exploits deep application in the narrow and curved vaginal tract of patients. Herein, we attempted a clinical trial to evaluate the vaginal cleaning effect of spraying plasma-activated water (PAW) to patients with vaginitis (46 patients). The efficacy was compared with treatment with betadine antiseptics used to treat bacterial vaginosis (40 patients). To evaluate the cleaning effect, Gram staining of the vaginal secretions was conducted before and after spraying PAW or betadine treatment (BT). Consequently, PAW-sprayed (PAWS) patients (22.3%) showed a better vaginal cleaning effect against Gram-positive and -negative bacteria than BT patients (14.4%). Moreover, 18 patients in the BT group showed worsened vaginal contamination, whereas five patients in the PAWS group showed worsened vaginal contamination. Taken together, the noncontact method of spraying cleaning water to the vagina exhibited a reliable vaginal cleaning effect without further bacterial infection compared with BT. Therefore, we suggest a clinical application of the spraying method using PAW for vaginal cleaning to patients with vaginitis without disinfectants and antibiotics.

Topics: Female; Humans; Povidone-Iodine; Vagina; Vaginitis; Vaginosis, Bacterial; Water

Recent evidence has associated bacterial vaginosis and trichomoniasis with several postoperative complications. We carried out a prospective study aiming to estimate the frequency of vaginitis in women wanting to make an artificial abortion and the possibility to influence this infections by local application of vaginal BETADINE suppositories in all forms of infectious vaginitis: Candida albicans, trichomonas vaginalis and bacterial vaginosis.

Topics: Abortion, Legal; Anti-Infective Agents, Local; Candidiasis, Vulvovaginal; Female; Humans; Povidone-Iodine; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Complications, Parasitic; Preoperative Care; Trichomonas Vaginitis; Vagina; Vaginitis; Vaginosis, Bacterial

Clinical experience proved the efficacy of Betadine suppository in the treatment of bacterial vaginosis and mycotic infections of the vagina. Vaginal infections, frequently observed in pregnancy, can led to maternal and fetal complications, thus Betadine should be used both for prevention and therapy. One can ask if iodine absorbed from the vagina can influence the fetal thyroid function? 64 pregnant women received 7 day Betadine suppository (200 mg polyvidonum-iodine PVP) treatment for colpitis on 37-40 gestational week with excellent therapeutic result. TSH levels were measured by immunoassay in the serum of newborns 4-5 days after delivery, no signs of hypothyroidism were observed. Authors recommended 7 day Betadine vaginal suppository regimen for the prevention of intrauterine infections, treatment of mixed (bacterial, mycotical) vaginal infections, and restoration of the normal vaginal equilibrium of bacterias, since the risk of hypothyroidism is negligeable in mature newborns. In case of prematurity hypothyroidism is more frequently found also without iodine treatment therefore TSH level control is recommended in each case.

Topics: Anti-Infective Agents, Local; Bacterial Infections; Female; Humans; Infant, Newborn; Mycoses; Povidone-Iodine; Pregnancy; Pregnancy Complications, Infectious; Suppositories; Thyrotropin; Vagina; Vaginitis

Observations made with Betadine vaginal suppository in the treatment of 60 women suffering from colpitis have been discussed. The results of microbiological examinations of vaginal discharge sampled before 1 week and 4 weeks after the onset of therapy were compared. The effectiveness, tolerance of therapy, and the subjective opinion of the treated women were analysed. According to the results of the examinations in response to Betadine vaginal suppository the positivity of vaginal discharge for Candida decreased from 16 to 3 cases, for Trichomonas from 8 to 1 case, for aerobic bacteria from 16 to 7 cases, and the occurrence of mixed infections from 20 to 2 cases. Subjective complaints, burning, stinging sensation were rapidly moderated. In 52 of the 60 women discharge ceased, in another 4 cases it significantly decreased. In 51 cases burning sensation in the vagina ceased, and in 5 women it significantly decreased. Recurrence was not observed when a control examination was done after 1 month. The women tolerated Betadine vaginal suppository well and found it effective and easily applicable. At the beginning of treatment burning sensation was aggravated in 3 cases. These patients refused to further participate in the examination and received systemic treatment. Due to its broad bactericidal, fungicidal, protozoicide action and its good tolerability Betadine suppository was found to be useful for the local treatment of colpitis.

Topics: Administration, Intravaginal; Colposcopy; Female; Humans; Patient Satisfaction; Pessaries; Physical Examination; Povidone-Iodine; Recurrence; Treatment Outcome; Vaginal Smears; Vaginitis

Povidone-iodine pessaries (Betadine vaginal pessaries) containing 200 mg of povidone-iodine (PVP-I) in a water soluble base, are a widely used gynaecological preparation for treatment of vaginitis. We conducted a study on PVP-I pessaries at the reduced dose of one pessary daily for 7 days to suit conditions in Macau where patients are eager for a simple, short treatment course with confirmed clinical efficacy benefiting their professional and household essential requirements. Thirty-eight cases were selected for this particular clinical trial. These consisted of housewives, factory workers and professional girls (a sexually high risk group) who were suffering from vaginitis and complaining of vaginal discharge and irritation due to trichomonas, candida or non-specific vaginitis. After routine examination, including the collection of samples for microbiology, patients were treated with PVP-I pessaries 200 mg once a day for 7 days. The second microbiology samples were collected after the 7 day treatment period. Among the 38 cases, we had 30 cases with a complete record to allow us to make a summary and analysis of the trial. There were 14 cases of vaginitis due to yeasts and fungi infection, 3 cases of protozoa (trichomonas), and 13 cases due to non-specific pathogenic infections. 73.3% of cases had a complete symptomatic and microbiological cure and a further 16.7% had a microbiological cure with a good improvement in symptoms. No complications or side effects were found in the 7 days consecutive treatment course and inflammation quickly subsided during the course of treatment. PVP-I pessaries, used once daily for 7 days, seem to be an ideal treatment for cases who are likely to be unable to follow a longer treatment course.

Topics: Candidiasis, Vulvovaginal; Drug Administration Schedule; Female; Humans; Medical Records; Pessaries; Povidone-Iodine; Trichomonas Vaginitis; Vaginitis

In a double-blind randomized study we evaluated the efficacy of povidone-iodine in the treatment of clue cell-positive discharge (CCPD). Vaginal pessaries (200 mg povidone-iodine or placebo) were taken twice daily for five consecutive days. Although the regimen was reasonably well accepted, 'messiness' was reported by 13 of 33 women (39%). Of 44 women enrolled, treatment efficacy was evaluated in 28 women who had both follow-up visits. There was no significant difference in the efficacy of povidone-iodine and placebo pessaries, at either the first or the second follow-up visit (p values 0.46 and 1 respectively). It is concluded that the use of povidone-iodine pessaries, at least in the regimen described, cannot be regarded as an effective therapy for CCPD.

Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Female; Gardnerella vaginalis; Haemophilus Infections; Humans; Pessaries; Placebos; Povidone; Povidone-Iodine; Vaginitis

The authors report the results achieved in a controlled clinical study carried out for evaluating the efficacy of some topical preparations in the treatment of the so-called non-specific cervicovaginitis. The best results have been observed in 55 patients treated with a 0.1% benzydamine solution, whose efficacy was found to be significantly greater than that of povidone-iodine vaginal suppositories or a 0.2% aluminium acetate solution that were used in an additional 45 patients suffering from non-specific vulvovaginitis and exocervicitis, according to a fully randomized experimental study protocol. The results obtained in the non-selected population of the present study confirm the usefulness of benzydamine vaginal douches in the therapy of non-specific inflammations involving the lower female genital apparatus.

Topics: Acetates; Administration, Intravaginal; Adult; Benzydamine; Double-Blind Method; Female; Humans; Pessaries; Povidone-Iodine; Pyrazoles; Random Allocation; Therapeutic Irrigation; Uterine Cervicitis; Vaginitis

In a study of 100 women with non-specific vaginitis, characterised by a vaginal discharge which was malodorous and pruritic in most cases and caused dyspareunia and dysuria in some, Gardnerella vaginalis was isolated in 46% of patients. When present, G vaginalis was significantly associated with Mycoplasma hominis and Bacteroides species. Isolation of G vaginalis was unrelated to the presenting symptoms. Treatment with povidone-iodine pessaries for two weeks produced no pronounced benefit, either clinically or microbiologically, compared with a placebo. Nevertheless, 68% of all patients followed reported improvement four weeks after the start of treatment. The findings suggest that G vaginalis is one cause of non-specific vaginitis, which is more likely to be seen in women using oral contraceptives and is usually cured spontaneously.

Topics: Adolescent; Adult; Clinical Trials as Topic; Contraceptives, Oral; Double-Blind Method; Female; Gardnerella vaginalis; Haemophilus Infections; Humans; Middle Aged; Povidone-Iodine; Vaginitis

The use of chlorhexidine gluconate (CHG) as an intraoperative vaginal preparation has been shown to be more effective than vaginal povidone-iodine (PI) in decreasing vaginal bacterial colony counts. However, PI remains the standard vaginal preparation because of concerns of CHG's potential for vaginal irritation. The primary outcome of this study is a comparison of the rate of patient-reported vaginal irritation between 2% CHG and PI.. Consecutive patients were enrolled in a pre-post study. Group 1 consisted of consecutive patients who received PI as a vaginal preparation. Group 2 consisted of consecutive patients who received 2% CHG as a vaginal preparation. Patients used a standardized instrument to report irritation to trained nurse practitioners 1 day after surgery.. A total of 117 patients received vaginal operative preparation during the course of the study, with 64 patients in group 1 and 53 patients in group 2. Of the patients in group 1, 60 (93.7%) reported no vaginal irritation, 3 (4.69%) reported mild irritation, and 1 (1.56%) reported moderate irritation. In group 2 (2% CHG vaginal preparation), all of the patients (100%) reported no vaginal irritation (P = .38).. The use of 2% CHG as a vaginal operative preparation is not associated with increased vaginal irritation compared with PI in gynecologic surgery. It can safely be used, taking advantage of its efficacy in reducing vaginal bacterial colony counts.

Topics: Administration, Intravaginal; Anti-Infective Agents, Local; Chlorhexidine; Female; Gynecologic Surgical Procedures; Humans; Middle Aged; Povidone-Iodine; Surgical Wound Infection; Vaginitis

Topics: Administration, Intravaginal; Anti-Infective Agents, Local; Female; Humans; Povidone-Iodine; Remission Induction; Suppositories; Vagina; Vaginitis

Twenty women suffering from candidal, trichomonal and non-specific vaginitis were treated by povidone-iodine vaginal pessaries twice daily for 14 days. Blood samples were obtained from patients before and 7 and 14 days after treatment for the determination of serum thyroid stimulating hormone, total thyroxine, free thyroxine, total triiodothyronine, free triiodothyronine, reverse triiodothyronine, thyroxine binding globulin and thyroglobulin by the corresponding specific 125I radioimmunoassay. In addition serum protein bound iodine was determined by a spectrophotometric method. Post-treatment values of these parameters after 7 and 14 days were not significantly different from the corresponding pretreatment values. Vaginal discharge disappeared in 82% of patients; with partial improvement in the remaining 18%. No clinical side effects and no clinical evidence of thyroid disorder were found in any of the women. These results indicate that treatment with povidone-iodine vaginal pessaries is effective in the treatment of different forms of vaginitis and their daily use in euthyroid, non-pregnant women is safe and has no effect on thyroid function.

Topics: Adolescent; Adult; Female; Humans; Pessaries; Povidone-Iodine; Thyroid Gland; Vaginitis

Twelve postmenopausal women who experienced frequent urinary tract infections were found to have atrophic vaginitis. Four of them who were taking sulfonamide preparations chronically also had an interstitial nephritis manifest by decreasing glomerular filtration rate and eosinophiluria. Treatment consisted of a Betadine douche daily for 1 week, administration of an appropriate nonsulfonamide antibiotic, and institution of estrogen therapy to restore glycogen deposition in the vaginal epithelium and promote return of a normal vaginal pH and bacterial flora. Prior to estrogen therapy, the frequency of infection was four per patient per year. During a follow-up observation period ranging from 2 to 8 years, there have been only four infections in the entire group. When sulfonamides were discontinued in the 4 patients with manifestations of interstitial nephritis, the eosinophiluria cleared, and the glomerular filtration rate increased significantly.

Topics: Estrogens; Female; Glomerular Filtration Rate; Humans; Menopause; Middle Aged; Nephritis, Interstitial; Povidone-Iodine; Recurrence; Sulfonamides; Therapeutic Irrigation; Urinary Tract Infections; Vaginitis

Fifty-six women with minor vaginal irritation, some associated with infertility, and with negative wet mount examination for common vaginal pathogens, used a disposable povidone-iodine-containing preparation (Betadine Medicated Douche) in a one-week trial. Of the 185 patient complaints, which included discharge, odor, pruritus, erythema, burning, and discomfort, 94 percent cleared completely and 4 percent were partially relieved. Odor cleared completely in 97 percent of affected cases and pruritus, discharge and chafing in 96, 91, and 100 percent, respectively. In all, 98 percent of the patients responded favorably. Those who became asymptomatic included women with past histories of repeated vaginal infections or on oral contraceptives, as well as a diabetic and patients with intrauterine devices. The douche caused no adverse effects and was well accepted by the patients. The present results favor short-term trial of the povidone-iodine douche in minor vaginal irritation of unknown etiology, before full laboratory investigation is undertaken.

Topics: Adult; Female; Humans; Infertility, Female; Middle Aged; Povidone; Povidone-Iodine; Therapeutic Irrigation; Vaginitis

The purpose of this study was to find a barrier contraceptive agent capable of controlling infections and sexual transmission of Ureaplasma urealyticum from the female genital tract, especially to help reduce nongonococcal urethritis in males caused by this organism. Therefore, the in vitro antimicrobial activity of six intravaginal contraceptives and BetadineR against the eight serotypes of the organism was investigated. The results indicate that some of these contraceptives produce partial inhibition of the Ureaplasma at low dilutions, while BetadineR produces a ureaplasmacidal effect up to dilutions of 1:64. These effects appear not to be due primarily to the pH of these agents. Thus, some of these agents may have a potential role in controlling transmission of Ureaplasma urealyticum.. An in vitro study was conducted in an effort to find a barrier contraceptive agent capable of controlling infections and sexual transmission of Ureaplasma urealyticum from the female genital tract, especially to help reduce nongonococcal urethritis in males caused by this organism. The in vitro antimicrobial activity of 6 intravaginal contraceptives and Betadine against the 8 serotypes of the organism was investigated. All 8 serotypes of Ureaplasma urealyticum exhibited a uniform response to each of the different products tested. Metabolic inhibition of Ureaplasma was examined at 24, 48, and 72 hours. At 24 hours, metabolic inhibition was observed with 6 of the 8 agents tested. 2 of the agents, Betadine solution and Betadine vaginal gel, produced inhibition up to 1:64. 4 agents -- Emko foam, Delfen foam, Kormex ii, and Conceptrol -- exhibited inhibition at either 1:16 or 1:32. The 2 other agents, NeoSampoon and Encare Oval, failed to produce inhibition of the lowest dilution tested. There was no change in the observed endpoint of 1:64 for the Betadine preparations at 48 and 72 hours. 4 of the agents demostrated a decrease in the endpoint upon prolonged incubation to 72 hours, with growth of the organism in the lowest dilutions of Emko and Delfen foams. Results of subcultures of all dilutions of the agent-broth mixtures at 5 minutes showed that Betadine in its 2 forms tested, Koromex II and Conceptrol, produced apparent killing of Ureaplasma at dilutions of 1:32, 1:4, and 1:4 respectively. Subcultures after 24 hours of contact between the agent and Ureaplasma indicated a killing effect up to dilutions of 1:64 for the Betadine preparations and 1:4 for Meko foam. All other endpoints remained unchanged at 24 hours. The measurements of the pH of the emulsions and the pH of 1:1 mixture of U9B medium with the agent emulsion ranged from 4.0 (Concetrol) to 7.9 (NeoSampoon) for the agent emulsons and from 4.2 Conceptrol) to 7.3 (Neo Sampoon) for the the U9B-emulsion mixtures. Betadine solution and gel were found to have a pH of 2.5 in saline dilution and 3.5 in solution with U9B broth. On the basis of these "in vitro" experiments, the intravaginal contraceptives may have a role in the prevention of sexually transmissble infection or colonization by Ureoplasma.

Topics: Contraceptive Agents, Female; Dose-Response Relationship, Drug; Female; Humans; Hydrogen-Ion Concentration; Male; Povidone; Povidone-Iodine; Sexually Transmitted Diseases; Ureaplasma; Urethritis; Vaginitis

Topics: Adult; Anti-Infective Agents, Local; Female; Humans; Middle Aged; Phenylmercury Compounds; Povidone-Iodine; Vaginitis

Topics: Adolescent; Adult; Candidiasis, Vulvovaginal; Female; Humans; Middle Aged; Pessaries; Povidone; Povidone-Iodine; Vaginitis

Topics: Catheterization; Female; Fetal Membranes, Premature Rupture; Humans; Infant, Newborn; Infant, Premature, Diseases; Povidone; Povidone-Iodine; Pregnancy; Puerperal Infection; Vaginitis

Topics: Adult; Female; Humans; Povidone; Povidone-Iodine; Suppositories; Vaginitis

Topics: Drug Evaluation; Female; Humans; Povidone; Povidone-Iodine; Therapeutic Irrigation; Vaginitis

Topics: Contraceptives, Oral; Female; Humans; Pessaries; Povidone; Povidone-Iodine; Pregnancy; Time Factors; Vaginitis

A regimen of treatment for vaginitis combining the use of a povidone-iodine solution for swabbing, a povidone-iodine vaginal gel for application at night and a povidone-iodine douche for use in the morning, was evaluated in 93 courses of treatment in 87 patients with monilial or trichomonal vaginitis or a combination of both. In monilial vaginitis, symptoms were cleared and negative laboratory results obtained in one to three weeks in all 74 courses of treatment. These results were obtained within one week in 52 cases and within two weeks in another 17. In four of five patients with trichomonal vaginitis, symptoms were cleared within three weeks. In the fifth, negative laboratory results were obtained but a mild discharge persisted at the end of the fourth week. In 14 courses for combined infections, symptoms were cleared within three weeks in 13, and the pathogens were absent in those patients within four weeks. In one patient the disease did not respond.

Topics: Adult; Candidiasis, Vulvovaginal; Female; Gels; Humans; Povidone; Povidone-Iodine; Pregnancy; Solutions; Trichomonas Vaginitis; Vaginitis

Topics: Anti-Infective Agents, Local; Candidiasis, Vulvovaginal; Female; Halogens; Humans; Hydrocarbons, Halogenated; Iodine; Povidone; Povidone-Iodine; Trichomonas Vaginitis; Vaginitis; Vulvovaginitis

Topics: Anti-Infective Agents; Anti-Infective Agents, Local; Female; Halogens; Humans; Hydrocarbons, Halogenated; Iodine; Povidone; Povidone-Iodine; Vaginitis